Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$280.96 -3.4%	$258.62	$141.98 ▼ $304.39	$36.37B	0.39	806,039 shs	1.07 million shs
BIIB Biogen	$139.16 -1.7%	$141.91	$128.51 ▼ $238.00	$20.37B	0.01	1.25 million shs	1.77 million shs
NBIX Neurocrine Biosciences	$116.18 +0.5%	$125.89	$105.18 ▼ $157.98	$11.58B	0.35	960,465 shs	1.31 million shs
UTHR United Therapeutics	$316.73 -1.0%	$343.28	$221.53 ▼ $417.82	$14.22B	0.64	445,356 shs	345,532 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+2.60%	+14.85%	+16.01%	+19.51%	+98.42%
BIIB Biogen	+0.50%	-1.35%	+0.68%	-4.98%	-35.08%
NBIX Neurocrine Biosciences	+3.29%	+3.68%	-4.22%	-15.33%	-18.26%
UTHR United Therapeutics	+2.19%	-0.95%	-11.42%	-11.36%	+34.45%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.5739 of 5 stars	3.4	5.0	4.3	3.2	2.5	0.6
BIIB Biogen	4.8475 of 5 stars	4.2	4.0	3.7	2.9	2.5	1.9
NBIX Neurocrine Biosciences	4.8916 of 5 stars	4.4	3.0	2.9	2.4	2.5	3.1
UTHR United Therapeutics	4.4039 of 5 stars	2.3	1.0	4.6	2.8	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.76	Moderate Buy	$312.30	11.16% Upside
BIIB Biogen	2.43	Hold	$213.33	53.30% Upside
NBIX Neurocrine Biosciences	2.83	Moderate Buy	$165.24	42.23% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$388.25	22.58% Upside

Current Analyst Ratings Breakdown

Latest NBIX, ALNY, BIIB, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/24/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$280.00 ➝ $328.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$338.00 ➝ $351.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$385.00 ➝ $390.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$310.00 ➝ $330.00
3/21/2025	ALNY Alnylam Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/21/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$300.00 ➝ $338.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$275.00 ➝ $287.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$302.00 ➝ $325.00
3/7/2025	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$185.00 ➝ $150.00

(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	16.18	N/A	N/A	$0.52 per share	540.31
BIIB Biogen	$9.68B	2.11	$22.85 per share	6.09	$114.71 per share	1.21
NBIX Neurocrine Biosciences	$2.36B	4.92	$3.38 per share	34.35	$25.97 per share	4.47
UTHR United Therapeutics	$2.88B	4.94	$19.05 per share	16.63	$127.35 per share	2.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.17	N/A	315.69	N/A	-12.37%	N/A	-6.83%	5/1/2025 (Estimated)
BIIB Biogen	$1.63B	$11.19	12.44	8.43	1.51	16.87%	14.98%	8.76%	4/23/2025 (Estimated)
NBIX Neurocrine Biosciences	$341.30M	$3.29	35.31	17.96	0.77	14.49%	13.38%	9.73%	4/29/2025 (Estimated)
UTHR United Therapeutics	$984.80M	$24.60	13.91	11.52	0.97	40.31%	19.22%	16.15%	4/29/2025 (Estimated)

Latest NBIX, ALNY, BIIB, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/26/2025	Q4 24	UTHR United Therapeutics	$6.10	$6.19	+$0.09	$6.19	$734.74 million	$735.90 million
2/13/2025	Q4 2024	ALNY Alnylam Pharmaceuticals	-$0.62	-$0.65	-$0.03	-$0.65	$580.62 million	N/A
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A
2/6/2025	Q4 2024	NBIX Neurocrine Biosciences	$1.62	$1.00	-$0.62	$1.00	$629.40 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	15.27	2.78	2.71
BIIB Biogen	0.27	1.35	0.90
NBIX Neurocrine Biosciences	N/A	3.40	3.28
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
NBIX Neurocrine Biosciences	92.59%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
BIIB Biogen	0.16%
NBIX Neurocrine Biosciences	4.30%
UTHR United Therapeutics	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,000	129.46 million	127.52 million	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
NBIX Neurocrine Biosciences	1,200	99.70 million	95.42 million	Optionable
UTHR United Therapeutics	980	44.91 million	39.33 million	Optionable

NBIX, ALNY, BIIB, and UTHR Headlines

Recent News About These Companies

KLP Kapitalforvaltning AS Invests $15.28 Million in United Therapeutics Co. (NASDAQ:UTHR)

March 25 at 5:19 AM | marketbeat.com

Teacher Retirement System of Texas Acquires 1,626 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 25 at 4:12 AM | marketbeat.com

1,287 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by AXQ Capital LP

March 24 at 5:42 AM | marketbeat.com

Summit Global Investments Has $12.73 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

March 23 at 5:49 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Stock Position Trimmed by Natixis Advisors LLC

March 23 at 3:54 AM | marketbeat.com

Investing Action Plan: Anduril Industries, United Therapeutics, Barstool In Miami

March 23 at 12:09 AM | investors.com

Harvest Fund Management Co. Ltd Purchases 2,021 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 22 at 5:02 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Corient Private Wealth LLC

March 22 at 4:10 AM | marketbeat.com

Buy Recommendation for United Therapeutics: Undervalued Potential in IPF Treatment with Tyvaso

March 21, 2025 | tipranks.com

Generali Asset Management SPA SGR Invests $3.01 Million in United Therapeutics Co. (NASDAQ:UTHR)

March 21, 2025 | marketbeat.com

Zacks Research Issues Pessimistic Outlook for UTHR Earnings

March 21, 2025 | americanbankingnews.com

Vinva Investment Management Ltd Sells 10,085 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 20, 2025 | marketbeat.com

Zacks Research Brokers Lower Earnings Estimates for UTHR

March 20, 2025 | marketbeat.com

Thrivent Financial for Lutherans Acquires 189,967 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 20, 2025 | marketbeat.com

United Therapeutics price target lowered to $314 from $328 at BofA

March 19, 2025 | markets.businessinsider.com

Short Interest in United Therapeutics Co. (NASDAQ:UTHR) Increases By 18.8%

March 19, 2025 | marketbeat.com

51,744 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Raymond James Financial Inc.

March 18, 2025 | marketbeat.com

Brandes Investment Partners LP Has $524,000 Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

March 17, 2025 | marketbeat.com

Swiss National Bank Lowers Position in United Therapeutics Co. (NASDAQ:UTHR)

March 17, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

March 17, 2025 | marketbeat.com

Globeflex Capital L P Trims Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

March 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX, ALNY, BIIB, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$280.96 -9.74 (-3.35%)

Closing price 04:00 PM Eastern

Extended Trading

$287.30 +6.34 (+2.25%)

As of 07:59 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$139.16 -2.44 (-1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$139.96 +0.80 (+0.57%)

As of 07:46 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Neurocrine Biosciences NASDAQ:NBIX

$116.18 +0.58 (+0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$117.62 +1.44 (+1.24%)

As of 07:07 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

United Therapeutics NASDAQ:UTHR

$316.73 -3.13 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$324.00 +7.27 (+2.30%)

As of 07:05 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time